Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 150
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 151
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
LATEST NEWS UPDATES | Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee

Pharma firms ‘push’ costly insulin at patients’ expense -Rupali Mukherjee

Share this article Share this article
published Published on Aug 30, 2015   modified Modified on Aug 30, 2015
-The Times of India

This may come as a shocker. Newer and more expensive categories of insulin are being aggressively "pushed" by drug companies, and, hence, increasingly prescribed by physicians for diabetics. The newer, second generation (rapid and long acting) versions are priced around Rs 500, three to four times costlier than the older versions - increasing the cost of treatment. Diabetes is growing alarmingly in India, with over 65 million patients now. About 30-35% of these are on insulin, while 70-80% of them prescribed insulin therapy in their lifetime.

These aggressive promotions are rampant globally too, with the surge in cost of diabetes therapy sparking off a debate in the medical fraternity, and among patients.

The matter assumes significance as it was discussed at the annual American Diabetic Association held in Boston recently. For years, drugmakers' reputations have been tarnished due to unethical and aggressive prescription promotion to doctors.

Says Anoop Misra, chairman Fortis Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology: "I strongly believe that some newer and costly insulin are being 'pushed' to physicians and patients India, while it has been inferred from debates even in US (in the recent American Diabetes Association Congress) that there is no advantage of (using) newer insulin that are nearly 4-6 times costlier than older insulin. It is rational, both scientifically and economically, to use low cost insulin in most cases, and particularly in economically challenged populations."

In the US, apparently, prices have hit the roof over the past decade. Cumulative inflation has risen 20%, whereas prices of several insulin have increased by a staggering 300-500%, with even insured patients feeling the pinch, experts say. In India, basal second generation (degludec) insulin costs around Rs 1,800, over three times the first generation (glargine) at Rs 500. Similarly, the second generation 'rapid and long acting' (human) insulin are priced around Rs 500, as against the first generation ones at Rs 150.

The older insulin, while less commonly used, are as effective as the analogs (new versions) at controlling blood glucose for most patients with type 2 diabetes, but at a lower price, experts say.

As far as clinical outcomes are concerned, despite the increased use of the newer versions, their superiority compared with human insulin is not well established, particularly for type 2 diabetes. The original regular insulin has a duration of action of about 8 hours, making it poorly suited to provide 24-hour basal coverage.

The Times of India, 30 August, 2015, http://timesofindia.indiatimes.com/business/india-business/Pharma-firms-push-costly-insulin-at-patients-expense/articleshow/48727726.cms


Related Articles

 

Write Comments

Your email address will not be published. Required fields are marked *

*

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close